|First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia|
|Tsai, Shih-Tzer1; Pathan, Faruque2; Ji, Linong3; Yeung, Vincent Tok Fai4; Chadha, Manoj5; Suastika, Ketut6; Son, Hyun Shik7; Tan, Kevin Eng Kiat8; Benjasuratwong, Yupin9; Thy Khue Nguyen10; Iqbal, Farrukh11|
|关键词||Asia Insulin Type 2 Diabetes Mellitus|
|刊名||JOURNAL OF DIABETES|
|WOS标题词||Science & Technology|
|类目[WOS]||Endocrinology & Metabolism|
|研究领域[WOS]||Endocrinology & Metabolism|
|关键词[WOS]||GLYCEMIC CONTROL ; GLUCOSE CONTROL ; RISK-FACTORS ; NPH INSULIN ; MANAGEMENT ; GLARGINE ; PREVALENCE ; THERAPY ; COMPLICATIONS ; PROGRESSION|
Background: The First Basal Insulin Evaluation (FINE) Asia study is a multinational, prospective, observational study of insulin-naive Type 2 diabetes mellitus (T2DM) patients in Asia, uncontrolled (A1c >= 8%) on oral hypoglycemic agents, designed to evaluate the impact of basal insulin initiation.
Methods: Basal insulin was initiated with or without concomitant oral therapy and doses were adjusted individually. All treatment choices, including the decision to initiate insulin, were at the physician′s discretion to reflect real-life practice.
Results: Patients (n = 2679) from 11 Asian countries were enrolled (mean [+/- SD] duration of diabetes 9.3 +/- 6.5 years; weight 68.1 +/- 12.7 kg; A1c 9.8 +/- 1.6%). After 6 months of basal insulin (NPH insulin, insulin glargine, or insulin detemir), A1c decreased to 7.7 +/- 1.4%; 33.7% patients reached A1c <7%. Fasting blood glucose (FBG) decreased from 11.7 +/- 3.6 to 7.2 +/- 2.5 mmol/L and 36.8% of patients reached FBG <6.1 mmol/L. The mean daily insulin dose prescribed increased marginally from 0.18 to 0.23 U/kg per day at baseline to 0.22-0.24 U/kg per day at Month 6. Mean changes in body weight and reported rates of hypoglycemia were low over the duration of the study.
Conclusions: Initiation of insulin therapy is still being delayed by approximately 9 years, resulting in many Asian patients developing severe hyperglycemia. Initiating insulin treatment with basal insulin was effective and safe in Asian T2DM patients in a real-world setting, but insulin needs may differ from those in Western countries.
|资助机构||sanofi-aventis ; Servier ; AstraZeneca ; Roche Diagnostics|
|作者单位||1.PD Hinduja Natl Hosp & Med Res Ctr, Bombay, Maharashtra, India|
2.Mt Elizabeth Med Ctr, Singapore, Singapore
3.Med Univ Ho Chi Minh City, Dept Endocrinol, Ho Chi Minh City, Vietnam
4.Shaikh Zayed Postgrad Med Inst, Lahore, Pakistan
5.Birdem, Dept Clin Endocrinol, Dhaka, Bangladesh
6.Taipei Vet Gen Hosp, Taipei 11217, Taiwan
7.Peking Univ, Peoples Hosp, Dept Endocrinol, Beijing 100871, Peoples R China
8.Our Lady Maryknoll Hosp, Ctr Diabet Educ & Management, Hong Kong, Hong Kong, Peoples R China
9.Udayana Univ RSUP Denpasar, Dept Internal Med, Fac Med, Denpasar, Indonesia
10.Catholic Univ Korea, Uijeongbu St Marys Hosp, Dept Internal Med, Gyeonggi Do, South Korea
11.Phramongkutklao Hosp, Dept Med, Endocrine Unit, Bangkok, Thailand
|Tsai, Shih-Tzer,Pathan, Faruque,Ji, Linong,et al. First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia[J]. JOURNAL OF DIABETES,2011,3(3):208-216.|
|APA||Tsai, Shih-Tzer.,Pathan, Faruque.,Ji, Linong.,Yeung, Vincent Tok Fai.,Chadha, Manoj.,...&Iqbal, Farrukh.(2011).First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia.JOURNAL OF DIABETES,3(3),208-216.|
|MLA||Tsai, Shih-Tzer,et al."First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia".JOURNAL OF DIABETES 3.3(2011):208-216.|